144 related articles for article (PubMed ID: 18851692)
1. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.
Bambico FR; Gobbi G
Expert Opin Ther Targets; 2008 Nov; 12(11):1347-66. PubMed ID: 18851692
[TBL] [Abstract][Full Text] [Related]
2. Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Bambico FR; Duranti A; Tontini A; Tarzia G; Gobbi G
Curr Pharm Des; 2009; 15(14):1623-46. PubMed ID: 19442178
[TBL] [Abstract][Full Text] [Related]
3. Role of the endocannabinoid system in the formation and development of depression.
Zhou D; Li Y; Tian T; Quan W; Wang L; Shao Q; Fu LQ; Zhang XH; Wang XY; Zhang H; Ma YM
Pharmazie; 2017 Aug; 72(8):435-439. PubMed ID: 29441900
[TBL] [Abstract][Full Text] [Related]
4. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
Hill MN; Carrier EJ; McLaughlin RJ; Morrish AC; Meier SE; Hillard CJ; Gorzalka BB
J Neurochem; 2008 Sep; 106(6):2322-36. PubMed ID: 18643796
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system as a target for the treatment of cannabis dependence.
Clapper JR; Mangieri RA; Piomelli D
Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):235-43. PubMed ID: 18691603
[TBL] [Abstract][Full Text] [Related]
6. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Umathe SN; Manna SS; Jain NS
Behav Brain Res; 2011 Sep; 223(1):125-34. PubMed ID: 21549765
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium.
Brighton PJ; Marczylo TH; Rana S; Konje JC; Willets JM
Br J Pharmacol; 2011 Nov; 164(5):1479-94. PubMed ID: 21486283
[TBL] [Abstract][Full Text] [Related]
8. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
9. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test.
Lisboa SF; Resstel LB; Aguiar DC; Guimarães FS
Eur J Pharmacol; 2008 Sep; 593(1-3):73-8. PubMed ID: 18691568
[TBL] [Abstract][Full Text] [Related]
10. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
13. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
14. N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus.
Gobira PH; Lima IV; Batista LA; de Oliveira AC; Resstel LB; Wotjak CT; Aguiar DC; Moreira FA
J Psychopharmacol; 2017 Jun; 31(6):750-756. PubMed ID: 28583049
[TBL] [Abstract][Full Text] [Related]
15. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Medeiros P; de Freitas RL; Silva MO; Coimbra NC; Melo-Thomas L
Neuroscience; 2016 Nov; 337():17-26. PubMed ID: 27595886
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein.
Pelorosso FG; Gago JE; Del Rey G; Menéndez SD; Errasti AE; Rothlin RP
Eur J Pharmacol; 2009 Jan; 602(1):176-9. PubMed ID: 19022239
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
Gobbi G; Bambico FR; Mangieri R; Bortolato M; Campolongo P; Solinas M; Cassano T; Morgese MG; Debonnel G; Duranti A; Tontini A; Tarzia G; Mor M; Trezza V; Goldberg SR; Cuomo V; Piomelli D
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18620-5. PubMed ID: 16352709
[TBL] [Abstract][Full Text] [Related]
18. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Romero TR; Pacheco Dda F; Duarte ID
Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
[TBL] [Abstract][Full Text] [Related]
19. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
20. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.
Vlachou S; Nomikos GG; Panagis G
Psychopharmacology (Berl); 2006 Oct; 188(3):293-305. PubMed ID: 16953388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
